DXCM: Dexcom stock analysis

50/100

● Neutral Zone

No directional signal

The canonical InvestCompass profile currently shows mixed evidence without a clear directional edge.

Global score threshold

Buy Zone ≥ 80

Partial Buy Zone ≥ 65

Neutral Zone ≥ 45

Partial Sell Zone ≥ 25

Sell Zone < 25

Dexcom

DXCM

Market: SPX
Sector:: Healthcare
Industry: Medical Devices

About the company

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

Global score detail

Breakdown of the 4 modules in the global score (Macro, Sector, Fundamental, Technical)

1. Macro(15%)57/100

Sector(30%)45/100

Fundamental(25%)88/100

Technical(30%)19/100

Macro — Full analysis workspace

Fundamental — Full analysis workspace

Sector — Full analysis workspace

Technical — Full analysis workspace

Fundamentals and peer comparison

Signals and trade plan

Current Price

$87.71

Period High

$92.59

Period Low

$54.11

Analyst Target

$96.46

10.0% upside

Price history

Loading chart...

Moving averages

Technical indicators

Moving averages

Technical indicators

AI and news commentary

Unlock full analysis

InvestCompass provides analysis tools, not financial advice. Data may be delayed.